Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1536194

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1536194

Autoimmune Hemolytic Anemia Therapeutics

PUBLISHED:
PAGES: 197 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 5600
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 16800

Add to Cart

Global Autoimmune Hemolytic Anemia Therapeutics Market to Reach US$873.7 Million by 2030

The global market for Autoimmune Hemolytic Anemia Therapeutics estimated at US$535.6 Million in the year 2023, is expected to reach US$873.7 Million by 2030, growing at a CAGR of 7.2% over the analysis period 2023-2030. Corticosteroids, one of the segments analyzed in the report, is expected to record a 8.0% CAGR and reach US$509.1 Million by the end of the analysis period. Growth in the Monoclonal Antibodies segment is estimated at 6.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$145.9 Million While China is Forecast to Grow at 11.7% CAGR

The Autoimmune Hemolytic Anemia Therapeutics market in the U.S. is estimated at US$145.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$194.7 Million by the year 2030 trailing a CAGR of 11.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.1% and 7.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Global Autoimmune Hemolytic Anemia Therapeutics Market - Key Drivers and Trends Summarized

Autoimmune Hemolytic Anemia (AIHA) therapeutics encompass a range of treatments aimed at managing and alleviating the symptoms of AIHA, a rare condition where the immune system mistakenly attacks and destroys the body's red blood cells. This leads to hemolytic anemia, characterized by fatigue, pallor, shortness of breath, and jaundice. The therapeutic landscape includes corticosteroids, immunosuppressive agents, monoclonal antibodies, and supportive treatments such as blood transfusions. The primary goal of these therapeutics is to reduce the rate of red blood cell destruction, manage the immune response, and address symptoms to improve patient quality of life.

In recent years, the development of AIHA therapeutics has seen significant advancements, driven by a deeper understanding of the disease’s pathophysiology and immune mechanisms. Corticosteroids like prednisone are often the first line of treatment due to their efficacy in reducing inflammation and immune activity. However, long-term use can result in adverse effects, prompting the need for alternative therapies. Immunosuppressive agents such as rituximab, a monoclonal antibody targeting CD20 on B-cells, have shown promise in refractory cases where steroids are insufficient. Additionally, novel therapies are being explored, including complement inhibitors and small molecule drugs that specifically target pathways involved in red blood cell destruction. These innovations are expanding the treatment arsenal and offering hope for better management of AIHA.

The growth in the AIHA therapeutics market is driven by several factors, including advancements in targeted therapies, increased diagnostic awareness, and a rising prevalence of autoimmune disorders. Technological progress in biotechnology has enabled the development of more effective and specific treatments, such as monoclonal antibodies and novel immunomodulatory drugs, which have improved patient outcomes. Increased awareness and improved diagnostic techniques are leading to earlier and more accurate detection of AIHA, facilitating timely intervention and better management of the disease. Additionally, the rising prevalence of autoimmune conditions globally is contributing to a larger patient population requiring treatment. Pharmaceutical companies are investing in research and development to bring new therapies to market, spurred by the growing recognition of unmet medical needs in this area. These factors collectively drive the expansion of the AIHA therapeutics market, offering new hope for patients and healthcare providers.

Select Competitors (Total 56 Featured) -

  • Alkem Laboratories Limited
  • Alnylam Pharmaceuticals, Inc.
  • Alpine Immune Sciences
  • Amneal Pharmaceuticals Inc.
  • Annexon Biosciences
  • Apellis Pharmaceuticals Inc.
  • argenx SE
  • Incyte Corporation
  • Johnson & Johnson Services, Inc.
  • Lupin Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Rigel Pharmaceuticals Inc.
  • Sanofi SA;
Product Code: MCP26626

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Autoimmune Hemolytic Anemia Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Autoimmune Hemolytic Anemia Drives Demand for Therapeutics
    • Advancements in Diagnostic Technologies Propel Growth in Anemia Therapeutics Market
    • Growing Awareness of Rare Diseases Spurs Demand for Specialized Treatments
    • Innovations in Monoclonal Antibody Therapies Generate Market Interest
    • Expansion of Biopharmaceutical Sector Drives Adoption of Novel Therapies
    • Advances in Immunotherapy Techniques Generate New Market Opportunities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Autoimmune Hemolytic Anemia Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 15: USA Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: USA 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 17: Canada Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 18: Canada Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: Canada 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • JAPAN
    • Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 20: Japan Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Japan Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: Japan 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • CHINA
    • Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 23: China Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: China Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: China 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • EUROPE
    • Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • FRANCE
    • Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 32: France Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: France Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: France 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • GERMANY
    • Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 35: Germany Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Germany Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Germany 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 38: Italy Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Italy Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Italy 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 41: UK Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: UK Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: UK 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 44: Spain Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Spain Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Spain 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 47: Russia Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Russia Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Russia 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Rest of Europe Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Rest of Europe 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 59: Australia Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Australia Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Australia 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • INDIA
    • Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 62: India Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: India Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: India 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 65: South Korea Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: South Korea Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: South Korea 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Rest of Asia-Pacific Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Rest of Asia-Pacific 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 77: Argentina Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Argentina Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Argentina 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 80: Brazil Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Brazil Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Brazil 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 83: Mexico Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Mexico Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Mexico 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Latin America Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Rest of Latin America 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 95: Iran Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Iran Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Iran 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 98: Israel Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Israel Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Israel 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Saudi Arabia Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Saudi Arabia 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 104: UAE Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: UAE Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: UAE 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Rest of Middle East Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Rest of Middle East 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030
  • AFRICA
    • Autoimmune Hemolytic Anemia Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 110: Africa Recent Past, Current & Future Analysis for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Africa Historic Review for Autoimmune Hemolytic Anemia Therapeutics by Type - Corticosteroids, Monoclonal Antibodies and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Africa 16-Year Perspective for Autoimmune Hemolytic Anemia Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids, Monoclonal Antibodies and Other Types for the Years 2014, 2024 & 2030

IV. COMPETITION

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!